๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Remission induction in acute nonlymphocytic leukemia: Comparison of a seven-day and ten-day infusion of cytosine arabinoside in combination with adriamycin

โœ Scribed by Preisler, H. ;Bjornsson, S. ;Henderson, E. S. ;Hryniuk, W. ;Higby, D. ;Freeman, A. ;Naeher, Carl


Publisher
John Wiley and Sons
Year
1979
Tongue
English
Weight
370 KB
Volume
7
Category
Article
ISSN
0098-1532

No coin nor oath required. For personal study only.

โœฆ Synopsis


Forty-six previously untreated patients with acute nonlymphocytic leukemia were treated with a remission induction regimen consisting of three daily doses of Adriamycin (30 mg/m2/day) and a ten-day continuous infusion of cytosine arabinoside (ara C) (100 mg/m2/day). The overall remission rate was 72%, with 88% of the patients less than 50 and 62% of patients greater than 50 years old achieving complete remission status. Thirty-one of the 33 complete remissions occurred after a single course of chemotherapy. Retrospective comparison of this regimen with its predecessor (identical, except that a seven-day infusion of ara C was administered) demonstrated that the increase in duration of ara C administration resulted in greater antileukemic effectiveness without an increase in hematologic toxicity to the patient.


๐Ÿ“œ SIMILAR VOLUMES


A comparison of two schedules of cytosin
โœ Slevin, M. L. ;Rohatiner, A. Z. S. ;Dhaliwal, H. S. ;Henry, G. P. ;Bell, R. ;Lis ๐Ÿ“‚ Article ๐Ÿ“… 1982 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 368 KB ๐Ÿ‘ 1 views

The most effective schedule of cytosine arabinoside (Ara-C) administration remains controversial and is further confused by the use of combination chemotherapy. Two remission induction regimens comprising adriamycin, Ara-C, and 6-thioguanine have been compared in patients with acute myelogenous leuk

Vincristine (NSC-67574), cytosine arabin
โœ Sartiano, George P. ;Pfrimmer, Wayne J. ;Turner, A. Robert ๐Ÿ“‚ Article ๐Ÿ“… 1978 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 412 KB

Fifteen newly diagnosed unselected adult patients with acute nonlymphocytic leukemia were treated in a pilot study of the combination of vincristine, cytosine arabinoside, 6-thioguanine, and daunorubicin (VAT-D) for remission induction therapy. Eleven of fifteen (75%) achieved a remission bone marro